Aurobindo pharma stock recommendation
Stock Code: NSE » AUROPHARMA AND BSE » 524804. 363.65 -49.55 (-11.%). Details, Technicals for, 19-03-2020. Open, 425, Resistance 3, 499.1. Last close 3 days ago -(Karvy Fintech Pvt Ltd.) Karvy Selenium Tower B, Plot 31-32,Gachibowli, Financial District,Nanakramguda,Hyderabad. About Aurobindo Pharma You can also check AUROPHARMA share price target recommended by Hot Stocks: Here's why you should sell Aurobindo Pharma, HUL in the short term 10 hours ago For Instant stock ideas: SUBSCRIBE to mobile notification on. ICICIdirect Mobile app… Open Recommendations. Click here to know more…
Value Research Stock Advisor has just released a new stock recommendation. Time Period, Aurobindo Pharma, S&P BSE Healthcare, S&P BSE Mid Cap
Welcome to Aurobindo Pharma USA: Committed to healthier life. Aurobindo adds value through superior customer service in the distribution of a broad line of generic pharmaceuticals, leveraging vertical integration and efficient controlled processes. 500 +ANDAs filed360 +Final approvalsManufacturing facilities approved by US FDA, Aurobindo Pharma Ltd (AUROPHARMA:NSI) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Aurobindo Pharma (₹599.5): The stock of Aurobindo Pharma skyrocketed 20 per cent with an upward gap, accompanied by extraordinary volume on February 19, by conclusively breaching a key long-term
AUROBINDO PHARMA analysts consensus, targets, ratings and recommendations | NATIONAL STOCK EXCHANGE OF INDIA: AUROPHARMA | NATIONAL STOCK EXCHANGE OF INDIA. AUROBINDO PHARMA analysts consensus, targets, ratings and recommendations | NATIONAL STOCK EXCHANGE OF INDIA: AUROPHARMA | NATIONAL STOCK EXCHANGE OF INDIA
Welcome to Aurobindo Pharma USA: Committed to healthier life. Aurobindo adds value through superior customer service in the distribution of a broad line of generic pharmaceuticals, leveraging vertical integration and efficient controlled processes. 500 +ANDAs filed360 +Final approvalsManufacturing facilities approved by US FDA, Aurobindo Pharma Ltd (AUROPHARMA:NSI) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Aurobindo Pharma (₹599.5): The stock of Aurobindo Pharma skyrocketed 20 per cent with an upward gap, accompanied by extraordinary volume on February 19, by conclusively breaching a key long-term
Shareholder Information→Shareholder StructureShare PerformanceFinancial HighlightsL
24 Feb 2020 Aurobindo Pharma, Ambuja Cements, Max Financial and Tube Investments are the stocks in news moving BSE Sensex and NSE Nifty today. Updated With Stock Market News On BloombergQuint. Recommended for you. We analyse every Aurobindo Pharma stock recommendation and show you their performance. Get Aurobindo Pharma detailed broker calls screener with many filters. AUROBINDO PHARMA analysts consensus, targets, ratings and recommendations | NATIONAL STOCK EXCHANGE OF INDIA: AUROPHARMA | NATIONAL STOCK EXCHANGE OF INDIA. AUROBINDO PHARMA analysts consensus, targets, ratings and recommendations | NATIONAL STOCK EXCHANGE OF INDIA: AUROPHARMA | NATIONAL STOCK EXCHANGE OF INDIA
14 Nov 2019 Sharekhan recommended Hold rating on Aurobindo Pharma with a target price of Rs 500 in its research report dated November 13, 2019.
Aurobindo Pharma: Economic Times — 4 stock recommendations by global brokerages. Feb 19, 2020. Feb 19, 2020. Aurobindo Pharma: Economic Times 24 Feb 2020 Aurobindo Pharma, Ambuja Cements, Max Financial and Tube Investments are the stocks in news moving BSE Sensex and NSE Nifty today. Updated With Stock Market News On BloombergQuint. Recommended for you.
We analyse every Aurobindo Pharma stock recommendation and show you their performance. Get Aurobindo Pharma detailed broker calls screener with many filters. AUROBINDO PHARMA analysts consensus, targets, ratings and recommendations | NATIONAL STOCK EXCHANGE OF INDIA: AUROPHARMA | NATIONAL STOCK EXCHANGE OF INDIA. AUROBINDO PHARMA analysts consensus, targets, ratings and recommendations | NATIONAL STOCK EXCHANGE OF INDIA: AUROPHARMA | NATIONAL STOCK EXCHANGE OF INDIA Aurobindo Pharma Ltd. analyst estimates by MarketWatch. View AUROPHARMA revenue estimates and earnings estimates, as well as analyst recommendations. BofA Securities maintains 'buy' rating on Aurobindo Pharma with a target price of Rs 634 per share. Unit-4 VAI status gives a sigh of relief for the company, it said, adding that the US FDA compliance score improves with this development. BofA on Aurobindo Pharma Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 24377.98 Crore) operating in Pharmaceuticals sector. Aurobindo Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 11922.63 Crore to Sales Value (97.26 % of Aurobindo Pharma Ltd (AUROPHARMA:NSI) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates.